We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+34.37%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$893M
AUM Growth
+$128M
Cap. Flow
-$69.5M
Cap. Flow %
-7.78%
Top 10 Hldgs %
49.95%
Holding
59
New
4
Increased
15
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
ACIU icon
AC Immune
ACIU
+$33.2M
2
CTMX icon
CytomX Therapeutics
CTMX
+$17.7M
3
MRSN
Mersana Therapeutics
MRSN
+$12.6M
4
REPL icon
Replimune Group
REPL
+$8.82M
5
OVID icon
Ovid Therapeutics
OVID
+$8.24M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$59.7M
2
ARRY
Array Biopharma Inc
ARRY
+$27.6M
3
XNCR icon
Xencor
XNCR
+$19.7M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$17.5M
5
PVLA
Palvella Therapeutics
PVLA
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGLS
51
DELISTED
Regulus Therapeutics
RGLS
$1.07M 0.12%
105,194
– –
CFRX
52
DELISTED
ContraFect Corporation
CFRX
$755K 0.08%
2,374
– –
XNCR icon
53
Xencor
XNCR
$1.49B
$28K ﹤0.01%
904
-592,561
-100% -$19.7M
IONS icon
54
Ionis Pharmaceuticals
IONS
$8.56B
– –
-9,399
Closed -$508K
KALV
55
DELISTED
KalVista Pharmaceuticals
KALV
– –
-252,693
Closed -$4.99M
PRNB
56
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-146,300
Closed -$4.01M
LOXO
57
DELISTED
Loxo Oncology, Inc
LOXO
– –
-3,944
Closed -$552K
MACK
58
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-917,579
Closed -$2.79M
IMDZ
59
DELISTED
Immune Design Corp.
IMDZ
– –
-5,185,383
Closed -$6.74M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2019 Portfolio in Review

As of Q1 2019, BVF Inc held 59 positions worth $893M, up 17% from $765M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

BVF Inc withdrew a net $69.5M in Q1 2019, closing 6 positions and reducing 14 holdings. Its most notable exit was Immune Design Corp., an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 83% a quarter earlier.

Against the trend, BVF Inc opened a new position in CytomX Therapeutics worth $12.9M.

  • BVF Inc's largest Q1 2019 buy was CytomX Therapeutics: 1,198,000 shares worth $12.9M.
  • BVF Inc added most to AC Immune in Q1 2019, an estimated $33.2M increase.
  • BVF Inc's biggest Q1 2019 reduction was ChemoCentryx, Inc., cutting an estimated $59.7M.
  • BVF Inc fully exited Immune Design Corp. in Q1 2019, selling an estimated $6.74M.
  • BVF Inc's ten largest holdings make up 50% of its $893M portfolio in Q1 2019.
  • BVF Inc opened 4 new positions and closed 6 in Q1 2019.
  • BVF Inc's portfolio value rose 17% quarter-over-quarter to $893M.

Based on BVF Inc's 13F filing for Q1 2019, filed 15 May 2019.